Novavax Reports Q3 Loss, Misses Revenue Estimates

Nasdaq2021-11-05

Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $4.04. This compares to loss of $3.21 per share a year ago. These figures are adjusted...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

MHh
2021-11-05
MHh
Because of all the delays? Means Q4 might be better? Especially with now many countries are advising for booster shots. But that would depend if the advisories allow for non-mRNA vaccines if the previous course was mRNA- based
Galaxy88
2021-11-05
Galaxy88
Looking for some good news to move up
HeroSmurf
2021-11-05
HeroSmurf
Gg
KeeBoonTong
2021-11-05
KeeBoonTong
Lalalala
- KeeBoonTong:
  lalala
BBBSIN
2021-11-05
BBBSIN
HUAT ah!
- BBBSIN:
  Cheong!
BabySim
2021-11-05
BabySim
Ok

发表看法

147

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1144097767?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-05 08:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144097767","market":"us","top_or_hot":-1,"title":"Novavax Reports Q3 Loss, Misses Revenue Estimates","media":"Nasdaq","content":"<div>\n<p>Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $4.04. This compares to loss of $3.21 per share a year ago. These figures are adjusted...</p>\n\n<a href=\"https://www.nasdaq.com/articles/novavax-nvax-reports-q3-loss-misses-revenue-estimates-2021-11-04\">网页链接</a>\n\n</div>\n","source":"lsy1603171495471","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Reports Q3 Loss, Misses Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Reports Q3 Loss, Misses Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 08:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/novavax-nvax-reports-q3-loss-misses-revenue-estimates-2021-11-04><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $4.04. This compares to loss of $3.21 per share a year ago. These figures are adjusted...</p>\n\n<a href=\"https://www.nasdaq.com/articles/novavax-nvax-reports-q3-loss-misses-revenue-estimates-2021-11-04\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://www.nasdaq.com/articles/novavax-nvax-reports-q3-loss-misses-revenue-estimates-2021-11-04","article_id":"1144097767","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144097767","pubTimestamp":1636070704,"sourceInfo":{"source_id":"lsy1603171495471","name":"Nasdaq"},"weMediaInfo":null,"summary":"Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate","collect":0,"end_time":0,"defaultTopTitle":"nasdaq.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯医药报告第三季度亏损，未预期收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $4.04. This compares to loss of $3.21 per share a year ago. These figures are adjusted for non-recurring items.\nThis quarterly report represents an earnings surprise of -6.68%. A quarter ago, it was expected that this vaccine maker would post a loss of $3.76 per share when it actually produced a loss of $4.75, delivering a surprise of -26.33%.\nOver the last four quarters, the company has not been able to surpass consensus EPS estimates.\nNovavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $178.84 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 41.71%. This compares to year-ago revenues of $157.02 million. The company has topped consensus revenue estimates two times over the last four quarters.\nThe sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\nNovavax shares have added about 75.1% since the beginning of the year versus the S&P 500's gain of 24.1%.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":846709799,"gmtCreate":1636110424754,"gmtModify":1636110653179,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"4091758936365950","authorIdStr":"4091758936365950"},"htmlText":"Because of all the delays? Means Q4 might be better? Especially with now many countries are advising for booster shots. But that would depend if the advisories allow for non-mRNA vaccines if the previous course was mRNA- based","listText":"Because of all the delays? Means Q4 might be better? Especially with now many countries are advising for booster shots. But that would depend if the advisories allow for non-mRNA vaccines if the previous course was mRNA- based","text":"Because of all the delays? Means Q4 might be better? Especially with now many countries are advising for booster shots. But that would depend if the advisories allow for non-mRNA vaccines if the previous course was mRNA- based","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846709799","repostId":1144097767,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":846564283,"gmtCreate":1636098247221,"gmtModify":1636098375899,"author":{"id":"4091842669394280","authorId":"4091842669394280","name":"Galaxy88","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4091842669394280","authorIdStr":"4091842669394280"},"htmlText":"Looking for some good news to move up&nbsp;","listText":"Looking for some good news to move up&nbsp;","text":"Looking for some good news to move up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846564283","repostId":1144097767,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":846222388,"gmtCreate":1636088221515,"gmtModify":1636088763955,"author":{"id":"3585642689958579","authorId":"3585642689958579","name":"HeroSmurf","avatar":"https://static.tigerbbs.com/6015b234d96461c6ef8db8d919ac3473","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3585642689958579","authorIdStr":"3585642689958579"},"htmlText":"Gg","listText":"Gg","text":"Gg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846222388","repostId":1144097767,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":846656586,"gmtCreate":1636080254859,"gmtModify":1636080740333,"author":{"id":"3578717603960999","authorId":"3578717603960999","name":"KeeBoonTong","avatar":"https://static.tigerbbs.com/815864515bc02d554ba00b04f5f46a1a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3578717603960999","authorIdStr":"3578717603960999"},"htmlText":"Lalalala","listText":"Lalalala","text":"Lalalala","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846656586","repostId":1144097767,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6461453,"gmtCreate":1636080265552,"gmtModify":1636080265579,"authorId":3578717603960999,"author":{"id":3578717603960999,"idStr":"3578717603960999","authorId":3578717603960999,"name":"KeeBoonTong","avatar":"https://static.tigerbbs.com/815864515bc02d554ba00b04f5f46a1a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":846656586,"type":1,"supId":0,"prevId":0,"content":"<u>lalala</u>","text":"<u>lalala</u>","html":"<u>lalala</u>"}],"langContent":"CN"},{"id":846637894,"gmtCreate":1636077175672,"gmtModify":1636079153662,"author":{"id":"3576973418636801","authorId":"3576973418636801","name":"BBBSIN","avatar":"https://static.tigerbbs.com/768828c81af5c2df7cda666c27aebbd6","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3576973418636801","authorIdStr":"3576973418636801"},"htmlText":"HUAT ah!&nbsp;","listText":"HUAT ah!&nbsp;","text":"HUAT ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846637894","repostId":1144097767,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6460573,"gmtCreate":1636077181147,"gmtModify":1636077181219,"authorId":3576973418636801,"author":{"id":3576973418636801,"idStr":"3576973418636801","authorId":3576973418636801,"name":"BBBSIN","avatar":"https://static.tigerbbs.com/768828c81af5c2df7cda666c27aebbd6","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":846637894,"type":1,"supId":0,"prevId":0,"content":"Cheong!","text":"Cheong!","html":"Cheong!"}],"langContent":"CN"},{"id":846603032,"gmtCreate":1636075686769,"gmtModify":1636075687071,"author":{"id":"3579673211261157","authorId":"3579673211261157","name":"BabySim","avatar":"https://static.tigerbbs.com/5c6f0cd54fab9f24929e66e54e08e3aa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579673211261157","authorIdStr":"3579673211261157"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846603032","repostId":1144097767,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":147,"commentSize":13,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144097767"}